FUJIFILM Europe will be attending this year’s
European Congress of Pathology (ECP) – taking place in Basel, Switzerland,
from the 3rd to the 7th of September – where the Medical
Informatics team will be showcasing Inspirata’s Dynamyx™ software. Digital pathology solutions
offer significant logistical and operational benefits compared to traditional
methods. Digitisation
facilitates clinical collaboration across organisations and regions, allowing
images and patient data to be shared in real time to create a global
community of consultants, educational institutions and specialists, who will
have the ability to access shared images, AI and case data in real time. This will help to reduce the
time to diagnosis and improve patient outcomes, as well as easing the burden
when the demand for histopathologists outstrips the supply. Dynamyx™ software is a vendor
agnostic, end-to-end digital pathology solution, offering an open
architecture that can be seamlessly integrated with scanners and LIMS.
Dynamyx™ software connects workflow and case management tools with image
evaluation and AI solutions. This significantly simplifies the workflow, as
everything can be found in one highly functional and user-friendly package.
In addition, AI can greatly improve the speed and accuracy of clinical
decision making through analysis of objective, quantitative data. Fujifilm
supports digital
pathology, helping to streamline the transition into the digital era by
providing a synergistic portfolio of technologies that help to unify, store,
analyse and visualise clinical data. Tim Wing, Head of Digital
Pathology at FUJIFILM Europe, explained: “Fujifilm has been a part of the
healthcare industry for a long time, and is now a global player in digital
pathology. We are very excited to be exhibiting at ECP, and believe that
Dynamyx™ software is an excellent system which, when combined with our
complete suite of Fujifilm digital imaging products, will support rapid dissemination of data to
clinicians. This will enable faster, more accurate diagnoses and, ultimately,
improve patient outcomes.” |
No comments:
Post a Comment